View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Anis Zgaya ... (+3)
  • Anis Zgaya
  • Louis Boujard
  • CFA
Anis Zgaya ... (+3)
  • Anis Zgaya
  • Louis Boujard
  • CFA
ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Njål Kleiven
  • Stian Wibstad
ABGSC Oil & Oil Services Research ... (+3)
  • ABGSC Oil & Oil Services Research
  • Lars Trongaard Brattli
  • Njål Kleiven
ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Njål Kleiven
  • Stian Wibstad
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
 PRESS RELEASE

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive ...

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy Strasbourg, France, and Lund, Sweden, October 20, 2025, 08:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment...

 PRESS RELEASE

Le virus oncolytique armé BT-001, développé par Transgene et BioInvent...

Le virus oncolytique armé BT-001, développé par Transgene et BioInvent, montre une activité antitumorale locale, à distance et durable chez des patients atteints de tumeurs avancées en échec thérapeutique BT-001, administré en combinaison avec pembrolizumab, est bien toléré et présente une activité antitumorale persistante dans des lésions injectées et non-injectées Les résultats obtenus soutiennent la poursuite du développement de BT-001 dans les tumeurs solides afin d'améliorer la réponse aux immunothérapies Strasbourg, France, et Lund, Suède, le 20 octobre 2025, 8 h 30 CEST – Transge...

ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Njål Kleiven
  • Stian Wibstad
Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk
Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk
 PRESS RELEASE

Subsea 7 S.A. - 3Q25 earnings call notification

Subsea 7 S.A. - 3Q25 earnings call notification Luxembourg – 13 October 2025 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) will publish its third quarter 2025 results for the period ended 30 September 2025 on Thursday 20 November 2025 at 08:00 CET. A conference call and simultaneous webcast for the investment community will be held on Thursday 20 November 2025 at 12:00 UK / 13:00 CET. From 08:00 CET the results announcement and the presentation to be reviewed during the conference call and webcast will be available on the Subsea7 website: Conference call registration: Phone:         -c...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch